Is BioArctic AB (publ) (BRCTF) a Buy, Sell, or Hold?
OTC : BRCTF
BioArctic AB (publ)
$31.78 USD
$0 (0.0%)
- Volume
- 250
- Average Volume
- 9
- Market Capitalization
- $2.82B
- P/E Ratio
- 128.38
- Dividend Yield
- 0.65%
- Price Target
- Year High
- $38.75
- Year Low
- $19.34
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.54
Company Overview
OTC
Gunilla Christina Osswald
Medical - Pharmaceuticals
Healthcare
BRCTF
141
SE
USD
Liquidity Metrics
0.02
6.54
6.54
3.03
0.00
Sales & Valuation
$1.99B
23.90
12.48
21.87
14.14
Profitability
$11.52
$1.02B
18.59%
36.07%
10.44%
7.96%
P/E Metrics
128.38
-1.68
-1.68
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
36.18
4/9
$2.2B
$2.68B
$481.21M
$401.67M
Key Metrics (TTM)
$26.23B
22.87
63.80
6.54
10.44%
8.88%
0.78%
4.58%
$36.64
-415 days
Company Executives
| Name | Title |
|---|---|
| Johanna Fälting | Chief R&D Officer and Head of Research & Development |
| Harald Borgeke | Head of Public Affairs |
| Gunilla Osswald | President & Chief Executive Officer |
| Pär Gellerfors | Co-Founder & Senior VP of Business Strategy |
| Emilie Ankarcrona Smith | General Counsel and Head of Legal & IP |
| Frida Lekander | Head of Marketing |
| Rebecca Kastell | Vice President & Head of HR |
| Mikael Moge | Vice President & Head of CMC |
| Anders Martin-Lof | Secretary of the Board & CFO |
| Oskar Bosson | Vice President and Head of IR & Communication |
| Per-Ola Freskgard | Chief Scientific Officer |
| Lars Lannfelt | Co-Founder, Senior Vice President of Medical science & Director |
Poll Results
No votes yet today — be the first to share your view!
About BioArctic AB (publ) (OTC:BRCTF) Stock
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, whi ... ch are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
2026-07-14 11:39:00
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving Leqembi over an average of 17 months. The results were consistent across sex, race, ethnicity and APOE genotype.
2026-06-22 01:52:00
STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. As part of the agreement, BioArctic will receive USD 30 million in upfront payment.
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
2026-05-30 04:31:00
STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028.
Bulletin from the Annual General Meeting in BioArctic AB (publ)
2026-05-28 13:34:00
STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of the income statement and the balance sheet: allocation of result and determination of the record date for the dividend The Annual General Meeting adopted the income statement and balance sheet for the company and for the group in accordance with the submitted accounting documents and resolved, in accordance with the board of directors' proposal, that a dividend of SEK 2 per share shall be paid, with 1 June 2026 as the record date for the dividend.
BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
2026-05-20 13:10:55
BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
BioArctic Interim Report for the period January - March 2026
2026-05-20 03:30:00
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks The application for marketing authorization for subcutaneous initiation treatment with Leqembi was granted Priority Review in China New long-term and real-world data for Leqembi, presented at the AD/PD™ conference in Copenhagen, showed that patients choose to remain on treatment over a long period and that the disease-slowing treatment effect was sustained for up to four years of treatment Sales of Leqembi exceeded EUR 500 M during Eisai's financial year 2025 (April 2025 – March 2026), triggering a second sales-related milestone payment of EUR 20 M Events after the end of the period The Swedish NT Council announced that it currently does not recommend the introduction of Leqembi in Swedish healthcare The FDA has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi® Iqlik™ by three months. The application concerns subcutaneous administration of Leqembi as an initiation treatment for early Alzheimer's disease.
2026-05-13 02:58:00
STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, BioArctic invites investors, analysts and media to a webcast (in English) on May 20, at 9:30 a.m CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, together with colleagues, will present and comment on the first quarter report, followed by a Q&A session.
Frequently Asked Questions
-
What is the current BioArctic AB (publ) (BRCTF) stock price?
-
BioArctic AB (publ)(OTC:BRCTF) stock price is $31.78 in the last trading session. During the trading session, BRCTF stock reached the peak price of $38.75 while $19.34 was the lowest point it dropped to. The percentage change in BRCTF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BRCTF stock was $0.
-
BRCTF's industry and sector of operation?
-
The OTC listed BRCTF is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of BRCTF?
-
Johanna Fälting | Chief R&D Officer and Head of Research & Development
Harald Borgeke | Head of Public Affairs
Gunilla Osswald | President & Chief Executive Officer
Pär Gellerfors | Co-Founder & Senior VP of Business Strategy
Emilie Ankarcrona Smith | General Counsel and Head of Legal & IP -
How many employees does BRCTF have?
-
Number of BRCTF employees currently stands at 141. BRCTF operates from Warfvinges vag 35, Stockholm, AB 112 51, SE.
-
Link for BRCTF official website?
-
Official Website of BRCTF is: https://www.bioarctic.se
-
How do I contact BRCTF?
-
BRCTF could be contacted at phone #46 86 95 69 30 and can also be accessed through its website. BRCTF operates from Warfvinges vag 35, Stockholm, AB 112 51, SE.
-
How many shares of BRCTF are traded daily?
-
The average number of BRCTF shares traded daily for last 3 months was 9.
-
What is the market cap of BRCTF currently?
-
The market value of BRCTF currently stands at $2.82B with its latest stock price at $31.78